What type of cancer do you have?

This helps us search the right trials. Criteria can differ between colon and rectal.

Colon cancer Tumor in the large intestine (not the last 15 cm) 76 trials Rectal cancer Tumor in the last 15 cm of the intestine, near the anus 226 trials Colorectal cancer (not sure) We show colon and rectal trials. You can refine later. 1.876 trials

Where can or do you want to be treated?

We filter trials by the centers available to you. You can broaden this later.

Spain Centers in Spanish territory only Europe Any EU country, UK or Switzerland Anywhere International. Some trials cover travel.

Which biomarkers do you know?

All fields are optional. The more detail, the more precise the matching. If you do not know a value, leave "I do not know" — we will show trials without that restriction.

⭐ Critical biomarkers Decisive for matching

MSI ? MSI / MMR MSI-H/dMMR responds very well to immunotherapy (pembrolizumab, nivolumab). MSS is the majority of CRC. Your report shows it after IHC or PCR/NGS.

KRAS ? KRAS The most relevant mutation in CRC. G12C has specific drugs (sotorasib, adagrasib). G13D and others fit pan-RAS like daraxonrasib. The exact variant changes the trials.

NRAS ? NRAS KRAS partner — they form the "RAS pathway". If one is mutated, anti-EGFR (cetuximab, panitumumab) does not work. Your NGS report almost always includes it.

BRAF ? BRAF Subset of 7-10% of CRC. V600E (class I) has approved encorafenib + cetuximab. Classes II/III respond differently. If absent in modern NGS, almost certainly Wild-type.

HER2 ? HER2 / ERBB2 Distinguishing levels is decisive. Positive (IHC 3+ or IHC 2+ FISH+) has T-DXd and trastuzumab+tucatinib. Low (IHC 2+ FISH-) is under research. Negative is most cases.

🧬 Other relevant biomarkers Optional — open more trials if you know them

TP53 ? TP53 The most common tumor suppressor in CRC (~60%). Some trials require it or stratify by it.

PIK3CA ? PIK3CA PI3K/AKT/mTOR pathway. Some mutations allow copanlisib or alpelisib in studies. ~15-20% of CRC.

CCNE1 ? CCNE1 Cyclin E1. Its amplification opens trials with WEE1 inhibitors (adavosertib) and others. Rare but actionable.

TMB

? TMB — Tumor Mutational Burden Tumor Mutational Burden. TMB-H (≥10 mut/Mb) has tumor-agnostic approval for pembrolizumab. Your NGS report usually includes it.

PD-L1

? PD-L1 Some trials require CPS≥1 or ≥10. For CRC less common than for other tumors, but relevant in MSI-H.

🔬 Rare biomarkers Less than 5% of CRC but decisive when present

NTRK ? NTRK Larotrectinib and entrectinib are approved tumor-agnostic for NTRK fusions. Only ~0.5% of CRC but spectacular responses.

RET ? RET Selpercatinib and pralsetinib approved for RET fusion. Very rare in CRC but searchable.

MET ? MET Inhibitors: tepotinib, capmatinib. Amplification or exon 14 skipping. Rare de novo in CRC, more common after anti-EGFR.

FGFR2 ? FGFR2 Pemigatinib, futibatinib. Fusions and amplifications in some basket trials.

POLE ? POLE Hypermutated tumors. Mutations in exonuclease domain generate very high TMB and excellent response to immunotherapy, even in MSS.

BRCA1/2 ? BRCA1/2 PARP inhibitors like olaparib in trials for tumors with HRD. Rare in CRC but relevant in hereditary colorectal.

Tell us how you are doing

The last two questions. Most trials need this info.

How many treatments have you had?

I have not started treatment yet I have had 1 line of treatment I have had 2 lines I have had 3 or more lines

How is your energy?

This is called ECOG in medical jargon. Pick the one that best describes you.

Fully active, no restrictions Normal life but I get tired more easily Out of bed less than 50% of the day, cannot work I need help with daily activities In bed or chair most of the time Not sure

Search summary

Here is what we will search. To change anything, go back.

When you press the button you will see the trials that match your answers. You can adjust the filters afterwards to refine them.